RDPAC: CRO Output Of China Will Double To RMB 11 Billion By 2015
This article was originally published in PharmAsia News
In its research report on innovation enhancement in China’s pharma industry released on Dec. 2, the R&D-based Pharmaceutical Association Committee (RDPAC) predicted that the country’s CRO (contract research organization) sector output will double to RMB 11 billion by 2015.
You may also be interested in...
Company says it has learnt from gene therapy flop Glybera, and claims best-in-class status for viral vector.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.